Australia · Delayed Price · Currency is AUD SomnoMed Statistics
Total Valuation
SomnoMed has a market cap or net worth of AUD 139.26 million. The enterprise value is 129.99 million.
| Market Cap | 139.26M |
| Enterprise Value | 129.99M |
Important Dates
The next estimated earnings date is Friday, February 20, 2026.
| Earnings Date | Feb 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SomnoMed has 218.44 million shares outstanding. The number of shares has increased by 75.54% in one year.
| Current Share Class | 218.44M |
| Shares Outstanding | 218.44M |
| Shares Change (YoY) | +75.54% |
| Shares Change (QoQ) | +0.79% |
| Owned by Insiders (%) | 8.36% |
| Owned by Institutions (%) | 26.12% |
| Float | 113.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 47.93 |
| PS Ratio | 1.25 |
| PB Ratio | 3.00 |
| P/TBV Ratio | 3.69 |
| P/FCF Ratio | 25.97 |
| P/OCF Ratio | 17.89 |
| PEG Ratio | 1.20 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 30.63, with an EV/FCF ratio of 24.24.
| EV / Earnings | -37.61 |
| EV / Sales | 1.17 |
| EV / EBITDA | 30.63 |
| EV / EBIT | n/a |
| EV / FCF | 24.24 |
Financial Position
The company has a current ratio of 1.51, with a Debt / Equity ratio of 0.17.
| Current Ratio | 1.51 |
| Quick Ratio | 1.10 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 1.89 |
| Debt / FCF | 1.50 |
| Interest Coverage | -0.77 |
Financial Efficiency
Return on equity (ROE) is -7.56% and return on invested capital (ROIC) is -0.84%.
| Return on Equity (ROE) | -7.56% |
| Return on Assets (ROA) | -0.26% |
| Return on Invested Capital (ROIC) | -0.84% |
| Return on Capital Employed (ROCE) | -0.59% |
| Weighted Average Cost of Capital (WACC) | 9.04% |
| Revenue Per Employee | 371,643 |
| Profits Per Employee | -11,521 |
| Employee Count | 300 |
| Asset Turnover | 1.48 |
| Inventory Turnover | 6.53 |
Taxes
In the past 12 months, SomnoMed has paid 2.69 million in taxes.
| Income Tax | 2.69M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.74% in the last 52 weeks. The beta is 0.92, so SomnoMed's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | +2.74% |
| 50-Day Moving Average | 0.74 |
| 200-Day Moving Average | 0.70 |
| Relative Strength Index (RSI) | 35.81 |
| Average Volume (20 Days) | 289,356 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SomnoMed had revenue of AUD 111.49 million and -3.46 million in losses. Loss per share was -0.02.
| Revenue | 111.49M |
| Gross Profit | 66.73M |
| Operating Income | -311,010 |
| Pretax Income | -763,863 |
| Net Income | -3.46M |
| EBITDA | 1.58M |
| EBIT | -311,010 |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 17.29 million in cash and 8.03 million in debt, with a net cash position of 9.27 million or 0.04 per share.
| Cash & Cash Equivalents | 17.29M |
| Total Debt | 8.03M |
| Net Cash | 9.27M |
| Net Cash Per Share | 0.04 |
| Equity (Book Value) | 46.39M |
| Book Value Per Share | 0.21 |
| Working Capital | 14.56M |
Cash Flow
In the last 12 months, operating cash flow was 7.78 million and capital expenditures -2.42 million, giving a free cash flow of 5.36 million.
| Operating Cash Flow | 7.78M |
| Capital Expenditures | -2.42M |
| Free Cash Flow | 5.36M |
| FCF Per Share | 0.02 |
Margins
Gross margin is 59.85%, with operating and profit margins of -0.28% and -3.10%.
| Gross Margin | 59.85% |
| Operating Margin | -0.28% |
| Pretax Margin | -0.69% |
| Profit Margin | -3.10% |
| EBITDA Margin | 1.42% |
| EBIT Margin | -0.28% |
| FCF Margin | 4.81% |
Dividends & Yields
SomnoMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -75.54% |
| Shareholder Yield | -75.54% |
| Earnings Yield | -2.48% |
| FCF Yield | 3.85% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 27, 2009. It was a reverse split with a ratio of 0.05.
| Last Split Date | Nov 27, 2009 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
SomnoMed has an Altman Z-Score of 1.99 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.99 |
| Piotroski F-Score | 4 |